According to the survey "Prevalence and Control Status of Diabetes Among Chinese Adults," the prevalence of diabetes among Chinese adults aged 18 and above has reached 11.6%, while the prevalence of prediabetes has surged to a staggering 50.1%. This means that among every 10 Chinese adults, 6 have abnormal blood glucose levels. Based on this ratio, China now has 130 million people with diabetes and nearly 500 million in the prediabetic stage.Diabetes has become one of China's most critical and challenging public health issues. The Healthy China Initiative (2019–2030) designates "Diabetes Prevention and Control Action" as one of its 15 key initiatives, setting specific targets for standardized diabetes management rates by 2022 and 2030.
Diabetes itself is not terrifying; what is terrifying are its complications. Therefore, people with diabetes must constantly monitor their blood glucose levels and manage them scientifically. Generally, they need to test their blood glucose at least seven times a day—before and after each meal, and before bed—to identify patterns in blood glucose fluctuations.Most blood glucose meters currently available require fingerstick blood sampling with test strips for testing. Since blood glucose levels fluctuate every three minutes in individuals, fingerstick monitoring often yields random blood glucose readings, leading to imprecise data. The frequency of seven tests per day can also cause significant resistance among many patients.
While numerous non-invasive blood glucose monitoring products and technologies exist today, most offer limited functionality. Non-invasive testing often suffers from multiple interference factors, poor correlation with actual blood glucose levels, and unclear physiological significance. Technical limitations include: accuracy (e.g., sensor specificity and sensitivity to glucose), physiological delays in glucose diffusion from blood vessels to skin, and the sophistication of data processing algorithms.On the other hand, reliability issues arise during product commercialization: Can data be automatically calibrated? Are contact materials safe? Is the operating system reliable (including batteries and hypoglycemia alerts)? Is it usable across diverse scenarios and settings (e.g., during exercise)? Thus, after years of exploration, non-invasive blood glucose monitoring technology remains immature.
Internationally, companies like Israel's OrSense are testing non-invasive monitoring systems based on spectral technology. Medtronic in the U.S. has developed the MiniMed non-invasive glucose monitor using iontophoresis principles, while Google has created contact lenses capable of detecting blood glucose levels. These companies have achieved certain milestones in non-invasive glucose monitoring.Domestically, progress has also been made in non-invasive blood glucose monitoring. Aton, a domestic brand in the field of AI preventive medicine that has consistently focused on chronic disease prevention, has been continuously researching non-invasive blood glucose monitoring technology.has been deeply researching non-invasive blood glucose monitoring technology. Currently, Andon has upgraded its non-invasive blood glucose monitoring service functionality. This feature not only avoids skin punctures to achieve non-invasive detection but also, compared to other non-invasive blood glucose monitoring services on the market, Andon's multidimensional non-invasive blood glucose monitoring service excels in data analysis. It can monitor 24-hour dynamic blood glucose levels while integrating the "gold standard" for blood glucose control—glycated hemoglobin (HbA1c). It is the first smart wearable device to integrate TIR (Time in Range), a critical reference indicator for diabetes complication risk. By comprehensively evaluating average glucose levels and fluctuation trends, it empowers users with a more holistic understanding of their glucose status.
For user convenience, it automatically analyzes and reports scheduled blood glucose readings every two hours. Additionally, 30 minutes after each scheduled reading, users can obtain real-time blood glucose values through manual measurement.Operation is simple, with automatic data recording and analysis, and test results and trends displayed visually. Technologically innovative, Andon's multidimensional non-invasive blood glucose monitoring service is based on a new generation of smart wearable watches. It utilizes health sensor data such as pulse wave spectrum, heart rate, blood pressure, and blood oxygen levels. Employing semi-supervised machine learning technology, it trains the DeepHeart deep neural network and combines it with pulse wave theory and big data analysis for more accurate monitoring data.
As mentioned earlier, diabetes complications are significant. Among all diabetes-related fatalities, over 75% result from macrovascular complications, with 75% attributed to coronary heart disease and 25% to cerebrovascular disease.Among diabetic patients, the mortality rate from coronary heart disease is four times higher than in non-diabetics, and 70% of diabetics develop macrovascular complications. Among all diabetes-related treatment costs, expenses for treating cardiovascular, cerebrovascular, and atherosclerotic diseases account for approximately 80%.The primary life-threatening complications for diabetic patients stem from the cardiovascular system. Beyond pioneering breakthroughs in non-invasive blood glucose monitoring, Andon has dedicated years to advancing cardiovascular and cerebrovascular monitoring and early warning systems. By integrating traditional Chinese medical philosophy with Western clinical practice through artificial intelligence and big data analytics, Andon has established a comprehensive cardiovascular and cerebrovascular monitoring and early warning service. This integrated platform combines health alerts, continuous monitoring, and management, enabling end-to-end visual health management for users—particularly for early warning of myocardial infarction andstroke, alongside autonomous monitoring of multidimensional health metrics, personalized health guidance, peer-to-peer health checks and sharing, and a comprehensive closed-loop ecosystem for holistic health management.
AnTun's significant advancements in non-invasive blood glucose monitoring will further enhance monitoring efficiency for patients, accelerate the widespread adoption of glucose testing, promote effective blood glucose management, reduce the incidence of diabetes complications, elevate user health standards, and contribute to China's healthcare initiatives.